
2.82 Delayed Data As of Apr 09 | ![]() Today’s Change | 0.87 Today|||52-Week Range 6.93 | +2.55% Year-to-Date |
Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data (Revised) Apr 09 / Zacks.com - Paid Partner Content | Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data Apr 07 / Zacks.com - Paid Partner Content |
Previous close | 2.87 |
Today’s open | 2.85 |
Day’s range | 2.80 - 2.93 |
Volume | 3,180,931 |
Average volume (3 months) | 6,926,050 |
Market cap | $792.5M |
Earnings growth (last year) | +53.85% |
Earnings growth (this year) | -28.57% |
Earnings growth (next 5 years) | -- |
Revenue growth (last year) | -52.23% |
P/E ratio | -- |
Price/Sales | 565.73 |
Price/Book | 4.49 |
Today’s change | Today’s % change | |
---|---|---|
ZIOPZIOPHARM Oncology In... | -0.07 | -2.06% |
HARPHarpoon Therapeutics... | +0.06 | +0.27% |
CGENCompugen Ltd | 0.00 | 0.00% |
VXRTVaxart Inc | -0.14 | -2.47% |
Next reporting date | May 13, 2021 |
EPS forecast (this quarter) | -$0.06 |
Annual revenue (last year) | $1.1M |
Annual profit (last year) | -$46.2M |
Net profit margin | -4,357.21% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |